What does “Humira LOE” mean?
“LOE” usually refers to “loss of exclusivity.” For Humira (adalimumab), this is the period when patent- and regulatory-based exclusivity protections start to fall away, allowing approved lower-cost competitors to enter the market.
When does Humira’s loss of exclusivity happen?
I can’t give a specific Humira LOE date from the information provided in your message (“Erosion humira loe”). Humira’s exact timeline depends on:
- the country (U.S. vs. EU vs. other markets),
- the specific formulation/presentation (for example, different strengths or dosing forms), and
- how courts and regulators treat patent validity and exclusivity extensions.
If you tell me the country/market you mean (e.g., “U.S. LOE” or “EU LOE”), I can narrow it to the right timeline.
Which companies are competing as Humira LOE approaches?
As Humira exclusivity erodes, biosimilar entrants typically launch around the time exclusivity expires, assuming they are approved and can market their product. The competitive landscape and which products launch first also depends heavily on geography and the timing of patent challenges and approvals.
Where to verify the Humira LOE date for your specific market
DrugPatentWatch.com tracks exclusivity and patent-expiration timelines for branded biologics and their competitive biosimilar entries. Use it to confirm the LOE date for the exact geography and product you’re researching: https://www.drugpatentwatch.com/
If you reply with the market (U.S., EU, UK, etc.) and whether you mean Humira “adalimumab” broadly or a specific strength/form, I can help you pin down the correct LOE reference point.
Sources:
1. DrugPatentWatch.com